Capital Bluecross STI Diagnostic Testing Coverage | OpenPayer
CurrentCapital BluecrossPolicy AHS - G2157
Diagnostic Testing of Common Sexually Transmitted Infections
Coverage criteria and limitations for laboratory testing of common STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum, Trichomonas vaginalis, HSV, HPV, and Mycoplasma genitalium) for Capital Bluecross members. Applies to ordering providers and laboratories submitting claims for STI diagnostic tests described in the policy.
Policy Summary
PayerCapital Bluecross
PolicyDiagnostic Testing of Common Sexually Transmitted Infections
Policy CodePolicy AHS - G2157
Change TypeNo material change
Effective Date
Next Review Date
Key ActionVerify benefit coverage and any prior authorization requirements at the time of request and document relevant clinical information to support testing.
No material clinical or coverage changes in this revision.
≥9distinct pathogens explicitly covered or discussed
MultipleNAAT/serology scenarios meeting coverage
Multipletests/approaches NOT covered
NCapplicable state listed
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
1.7M+
reported U.S. chlamydia cases (2018)
Coverage criteria and limitations
Covered and not covered testing criteria
Covered when described conditions are met for each pathogen:
Syphilis antibody testing - covered indications: Treponemal and nontreponemal antibody testing meets coverage when: (a) annual screening of asymptomatic persons in a high-risk category; (b) diagnosis of symptomatic individuals; (c) every 3 months for HIV-positive men or MSM; (d) once prior to allogeneic HCT in donor and recipient; (e) when a nontreponemal test is used as test-of-cure.
See policy Note 1 for high-risk definition and Note 2 for symptoms.
Syphilis molecular testing - not covered: Polymerase chain reaction (PCR) testing and nucleic acid amplification testing (NAAT) for syphilis DO NOT MEET COVERAGE CRITERIA.
Chlamydia NAAT - covered indications: NAAT for Chlamydia trachomatis meets coverage when: (a) annual screening of asymptomatic persons in a high-risk category; (b) diagnosis of symptomatic individuals; (c) diagnosis of suspected lymphogranuloma venereum (LGV); (d) at least three months after initial diagnosis as a test-of-cure.
Serologic testing for chlamydia or LGV does not meet coverage.
Gonorrhea NAAT and culture: NAAT for Neisseria gonorrhoeae meets coverage for annual asymptomatic high-risk screening and diagnosis of symptomatic individuals; culture for N. gonorrhoeae to determine antimicrobial susceptibility meets coverage when an individual does not respond to initial treatment.
Trichomonas testing: NAAT or PCR-based testing for Trichomonas vaginalis meets coverage for symptomatic individuals and for asymptomatic individuals in high-risk groups (e.g., concurrent/prior STI, STI clinic settings, transactional sex). Rapid enzyme immunoassay for Trichomonas is not covered.
Mycoplasma genitalium testing: NAAT for Mycoplasma genitalium meets coverage for symptomatic individuals (e.g., recurrent nongonococcal urethritis or recurrent cervicitis); screening asymptomatic individuals for M. genitalium is not covered.
HSV testing: NAAT/PCR for HSV-1/2 meets coverage for individuals with active genital ulcers or mucocutaneous lesions. Non-type-specific HSV immunoassays do not meet coverage. Type-specific serologic testing for HSV-2 (gG2) meets coverage in select clinical scenarios (recurrent/atypical symptoms with negative PCR/culture, clinical diagnosis without laboratory confirmation, or exposed partner with genital herpes); routine serologic screening of asymptomatic persons is not covered.
HPV testing: High-risk HPV testing meets coverage when used for diagnosis or assessment related to cancer or cancer therapy (e.g., adjunctive testing or genotyping where clinically indicated). HPV testing does not meet coverage for general STI screening in asymptomatic individuals, for diagnosis of anogenital warts, or for low-risk HPV types.
Multitarget PCR panels: When an individual meets covered conditions above, multitarget PCR panels limited to Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium meet coverage criteria.
PrEP-related testing
Covered testing in context of PrEP:
Preexposure prophylaxis (PrEP) baseline and monitoring: Prior to initiating PrEP: baseline serum creatinine, estimated creatinine clearance, HIV antigen/antibody testing (confirm negative within 1 week), hepatitis B/C screening, and pregnancy testing meet coverage. While on PrEP: HIV antibody testing every 3 months; serum creatinine at 3 months and then up to every 6 months; NAAT screening for gonorrhea and chlamydia by anatomic site (every 3 months for MSM and individuals with child-bearing potential; 9 months after initiation then every 6 months for other sexually active individuals); syphilis serology every 3 months for MSM and individuals with child-bearing potential (alternate intervals for others); pregnancy testing every 3 months.
Failure to document a negative HIV antigen/antibody within 1 week before PrEP initiation may affect coverage.
Testing coverage and clinical criteria
Clinical testing priorities and methods described in this section:
Chlamydia/Gonorrhea Diagnosis: Use NAAT (e.g., PCR, TMA, SDA) as the preferred diagnostic method for Chlamydia trachomatis and Neisseria gonorrhoeae; include extragenital (pharyngeal, rectal) testing at the anatomic site of exposure when indicated. Culture remains necessary for N. gonorrhoeae antimicrobial susceptibility testing and in certain medico-legal or treatment-failure contexts.
Syphilis Diagnosis: Employ two-tier serologic testing (treponemal and nontreponemal assays such as EIA/CLIA/TPPA plus RPR/VDRL) for screening and confirmation; NAAT/PCR for T. pallidum is not FDA-approved for routine genital syphilis testing and requires validated methods if used; direct detection (darkfield or PCR) is the gold standard for lesion-based early diagnosis when available.
HSV Testing: For active lesions, prefer NAAT/PCR or viral culture for diagnosis; serologic HSV-2 testing has high sensitivity but lower specificity and is associated with high false-positive rates in low-prevalence populations, so routine serologic screening is not recommended and is associated with potential psychosocial harms.
Testing and screening criteria
Testing and screening recommendations and rationale
Chlamydia/Gonorrhea screening: Screen sexually active females aged ≤24 years and women ≥25 years who are at increased risk; use NAATs for screening due to superior sensitivity and specificity (USPSTF Grade B).USPSTF Grade B
HSV testing: Do not perform routine serologic screening for HSV in asymptomatic persons; use NAAT or culture for lesion specimens; type-specific serology may be used in select scenarios (recurrent atypical lesions, partner with genital herpes, clinical diagnosis without lab confirmation).USPSTF/CDC
Covered testing criteria
Covered testing modalities and indications extracted from cited guideline text
Syphilis - lesion or suspected early disease: Direct detection methods (darkfield microscopy, PCR, immunohistochemistry) are gold standard for lesion-based diagnosis when available; when serology is used for presumptive diagnosis, both a nontreponemal test (RPR/VDRL) and a treponemal test are required.
CSF-VDRL and CSF analysis indicated for neurologic/ocular/otologic symptoms.
Syphilis - reflex and follow-up: If a treponemal test (TT) is positive, perform reflex quantitative non-treponemal testing (NTT) on the same serum; repeat serology after 1 month if TT positive and NTT negative with no chancre; follow-up serology schedule: primary/secondary/early latent at 1, 3, 6, and 12 months; late latent at 12 and 24 months.
Chlamydia: NAAT testing of first-catch urine or swab specimens is recommended for screening and diagnosis; perform extragenital testing at exposure site; test-of-cure recommended in select situations (e.g., pregnancy, uncertain compliance) at ~3–4 weeks post-treatment.
Chlamydia and Gonorrhea
Testing recommendations summarized from cited guidelines
Chlamydia/Gonorrhea testing: Use NAAT as the primary diagnostic test for chlamydia and gonorrhea on urine and genital (vaginal/cervical/urethral) swabs; consider NAAT for pharyngeal and rectal specimens after consulting the laboratory. Culture should be used for antimicrobial susceptibility or medico-legal confirmation; follow test-of-cure guidance where recommended.
Syphilis
Syphilis diagnostic approach per guidelines
Syphilis testing: Serologic testing is the usual diagnostic approach using treponemal-specific screening assays (EIA/CLIA) with confirmation by an additional treponemal test and quantitative non-treponemal testing (RPR/VDRL) as appropriate. For lesions, darkfield microscopy or PCR may be used when available. Repeat serologic follow-up depends on stage (see follow-up schedule).
CPS recommends prenatal screening at first visit and rescreening in high-risk women at 28–32 weeks.
Herpes Simplex Virus (HSV)
HSV diagnostic approach
HSV testing: Direct detection of HSV from lesions using NAAT/PCR is essential for diagnosis and typing; perform lesion swab testing and consider typing to distinguish HSV-1 from HSV-2 in newly diagnosed genital herpes cases. Culture may miss PCR-positive samples; NAATs are preferred.
HPV and Multiplex Assays
HPV and multiplex testing guidance
HPV and multiplex STI tests: High-risk HPV testing is recommended within cervical cancer screening algorithms for appropriate age groups (eg, persons ≥30) per guideline indications. Proprietary multiplex NAAT assays that detect multiple STIs (eg, CT/NG/TV/MG) and HPV genotyping assays are available and are listed with specific CPT/HCPCS codes; routine HPV testing for asymptomatic men or general STI screening is not recommended.
See proprietary assays (eg, Abbott Alinity m, Xpert CT/NG) listed in coding.
Explicit exclusions in this policy identify test methods that DO NOT MEET COVERAGE CRITERIA. Notable examples include: PCR/NAAT testing for Treponema pallidum (syphilis); serologic testing for Chlamydia trachomatis or LGV; rapid enzyme immunoassay (EIA) for Trichomonas vaginalis; and non-type-specific HSV immunoassays. The policy further states that nucleic acid quantification for several organisms (including Chlamydia, Gonorrhea, HSV-1/2, HPV, and T. pallidum) does NOT MEET COVERAGE CRITERIA due to insufficient evidence of clinical benefit.
The policy notes that NAAT/PCR for genital syphilis is not FDA‑approved and therefore DOES NOT MEET COVERAGE CRITERIA. It emphasizes that there is no internationally approved PCR for T. pallidum and that any molecular method used must be strictly validated and operated with appropriate quality controls if performed.
Routine serologic screening for genital herpes in asymptomatic adolescents and adults, including pregnant persons, DOES NOT MEET COVERAGE CRITERIA. Type‑specific HSV-2 serology (gG2) may be appropriate in limited circumstances (recurrent/atypical lesions with negative PCR/culture, clinical diagnosis without lab confirmation, or when a partner has genital herpes), but population screening is discouraged because of high false‑positive rates and potential psychosocial harms.
HPV testing in this policy is limited to indications related to cancer diagnosis or management (for example, NAAT for high‑risk HPV in the context of cervical cancer screening or pathology). The policy explicitly states that HPV testing DOES NOT MEET COVERAGE CRITERIA for use as part of general STI screening in asymptomatic individuals, for diagnosing anogenital warts, for screening low‑risk HPV types, or for routine testing in males.
Specific situations where HPV testing is not recommended include: screening male partners of women with HPV, testing women younger than 25 years as part of STI screening, using HPV NAAT to diagnose anogenital warts, and employing HPV testing as a general STI screen in asymptomatic people. The policy reinforces that HPV tests intended for cervical cancer screening are used per age‑based guidelines rather than as routine STI panels.
Procedure and proprietary codes listed in the policy are provided solely as a general billing reference. Inclusion of a CPT/HCPCS or proprietary test code in the document does not by itself imply coverage; providers should verify coding and coverage against member benefits and payer guidance.
The references section of the policy contains guideline and regulatory citations but does not itself state additional coverage exclusions or alter the exclusions listed in the main policy text.
Summary list of tests the policy identifies as not meeting coverage criteria or not medically necessary includes: PCR/NAAT for syphilis; serology for chlamydia or LGV; rapid EIA antigen tests for Trichomonas when used alone for screening; non‑type specific HSV immunoassays; routine HSV serologic screening in asymptomatic persons; nucleic acid quantification for multiple pathogens; and routine HPV testing for asymptomatic individuals outside cancer‑screening indications.
The policy highlights harms associated with HSV serologic screening: high false‑positive rates in low‑prevalence populations and consequent psychosocial harms. These concerns underpin the recommendation against routine serologic screening in asymptomatic adolescents and adults, including pregnant persons.
Because antigen‑detection POCTs for CT/NG demonstrate markedly lower sensitivity compared with laboratory NAATs, the policy does not support their use as the sole screening modality. Near‑patient NAATs may be acceptable where available, but standard lab NAAT remains the recommended approach for CT/NG detection.
International guidance cited in the policy indicates that darkfield microscopy is obsolete for routine syphilis diagnosis due to labor intensity and lower performance; PCR and other molecular direct‑detection methods are preferred for lesion testing when available, with the caveat that PCR assays for T. pallidum require strict validation.
The policy reiterates that routine HSV‑2 serologic screening and routine oncogenic HPV testing in asymptomatic individuals (including men and women under age thresholds) are not recommended. HPV testing should be applied according to cervical cancer screening guidelines (age‑based), and HSV diagnosis should rely on NAAT/culture of lesions in symptomatic cases.
No statements in the references section introduce additional not‑medically‑necessary determinations beyond those already specified in the policy body; the references list supports the clinical rationale for the policy's coverage and exclusion decisions.
Procedure and proprietary codes
Applicable CPT/HCPCS procedure codesmixed
No codes listed
Neutral assay method codes referencedmixed
NAAT
Nucleic acid amplification test (generic term used throughout document)
PCR
Polymerase chain reaction (method cited for multiple assays)
Covered CPT CodesCPT
No codes listed
Procedure codes (selection)CPT
82575
Creatinine; clearance.
86631
Antibody; Chlamydia.
86632
Antibody; Chlamydia, IGM.
86694
Antibody; herpes simplex, non-specific type test.
86695
Antibody; herpes simplex, type 1.
86696
Antibody; herpes simplex, type 2.
86803
Hepatitis C antibody.
87110
Culture, Chlamydia, any source.
87181
Susceptibility studies, antimicrobial agent; agar dilution method, per agent.
87490
Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, direct probe technique.
1–10 of 11
1/2
Procedure codes (continued)CPT
87528
Infectious agent detection by nucleic acid (DNA or RNA); Herpes simplex virus, direct probe technique.
87530
Infectious agent detection by nucleic acid (DNA or RNA); Herpes simplex virus, quantification.
87563
Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma genitalium, amplified probe technique.
87590
Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, direct probe technique.
87592
Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, quantification.
87660
Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, direct probe technique.
87661
Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique.
87797
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; direct probe technique, each organism.
87798
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism.
Immunoassay and proprietary codesmixed
87799
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism.
87808
Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Trichomonas vaginalis.
88341
Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure.
88342
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure.
88344
Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure.
0064U
Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative (BioPlex 2200 Syphilis Total & RPR Assay).
Infectious agent detection by nucleic acid (DNA), Chlamydia trachomatis and Neisseria gonorrhoeae, multiplex amplified probe technique (Xpert® CT/NG).
0354U
Human papilloma virus (HPV), high-risk types qualitative mRNA expression of E6/E7 by qPCR (PreTect HPV-Proofer).
0402U
Infectious agent (STI), Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, multiplex amplified probe technique (Abbott Alinity m STI Assay).
0500T
Infectious agent detection by nucleic acid (DNA or RNA), Human Papillomavirus (HPV) for five or more separately reported high-risk HPV types (genotyping).
Infectious agent detection by nucleic acid (DNA or RNA), Human Papillomavirus (HPV) for five or more separately reported high-risk HPV types (eg, genotyping)
No codes in referencesmixed
No codes listed
PrEP monitoring intervals (HIV and STI testing)
HIV antigen/antibody testing interval for PrEPBlood test to confirm negative HIV antibody result once every 3 months while on PrEP (document a negative test within 1 week before initiation).
STI NAAT interval for MSM and persons with child-bearing potential on PrEPNAAT screening for gonorrhea and chlamydia once every 3 months by anatomic site of exposure.
STI NAAT interval for other sexually active individuals on PrEPNine months after PrEP initiation and then once every 6 months thereafter for sexually active individuals (non‑MSM, non–child-bearing potential).
Renal monitoring on PrEPSerum creatinine and estimated creatinine clearance at 3 months after beginning PrEP and then up to once every 6 months thereafter.
Provider responsibilities and billing cautions
Documentation Required
Provider responsibilities and billing cautions
Actionable provider requirements, documentation expectations, and billing cautions for STI diagnostic testing. Includes proprietary assay code references, conditions that commonly trigger denials, required baseline and monitoring tests for PrEP, reflex testing and follow-up for syphilis, steps when gonorrhea treatment fails, recommendations for rapid NAAT use in acute settings, obligations when government coverage conflicts with this policy, and neurosyphilis/ocular syphilis evaluation guidance.
Proprietary assay codes are listed in the procedure code section (examples: 0064U, 0065U, 0096U, 0210U, 0353U, 0354U, 0402U). Document the specific proprietary assay name and the laboratory/manufacturer when ordering and in the medical record to support coverage determination.
Denial triggers (tests that DO NOT MEET COVERAGE CRITERIA and may be denied): PCR/NAAT to quantify organisms (e.g., quantification of Chlamydia trachomatis, N. gonorrhoeae, HSV-1/2, HPV, Treponema pallidum), serology testing for chlamydia/LGV, rapid Trichomonas enzyme immunoassay (EIA), and routine HSV screening. Ensure clinical justification and applicable indications are documented if these tests are ordered.
Before initiating or re-initiating HIV PrEP, providers must confirm a negative HIV antigen/antibody test within 1 week prior to starting therapy. Use laboratory-based blood testing or an FDA-approved rapid fingerstick blood test; do NOT use oral rapid tests for PrEP screening when possible.
Document HIV antigen/antibody testing and baseline renal function (serum creatinine and estimated creatinine clearance) in the medical record prior to PrEP initiation and per CDC monitoring schedule.
Clinical background and epidemiology
Background: Sexually transmitted infections (STIs) are common bacterial and viral infections transmitted through sexual contact and can cause significant morbidity if untreated, including pelvic inflammatory disease and infertility (chlamydia), disseminated and antimicrobial‑resistant infection (gonorrhea), neurologic and congenital disease (syphilis), and HPV‑associated cancers. The policy addresses diagnostic testing priorities for common STIs— including Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum, Trichomonas vaginalis, Herpes simplex virus, Human papillomavirus, and Mycoplasma genitalium—and ties coverage decisions to evidence‑based testing strategies and guideline recommendations.
Definitions and test method terms
NAAT definition
NAAT (general)Nucleic acid amplification testing (NAAT) is a molecular method that detects pathogen-specific DNA or RNA and is the preferred diagnostic test for Chlamydia trachomatis and Neisseria gonorrhoeae; can be performed on urine and genital/extragenital swabs.
Common NAAT methodsIncludes PCR (polymerase chain reaction), TMA (transcription-mediated amplification), and SDA (strand displacement amplification).
Use casesRecommended for screening asymptomatic high-risk individuals and for diagnosis of symptomatic persons; near‑patient NAATs may be used in acute settings.
gG2 definition (HSV-2 serology)
gG2 (HSV-2 type-specific antigen)gG2 refers to glycoprotein G2, used in type-specific serologic assays to detect prior HSV-2 infection.
Clinical use
Policy Summary
PayerCapital Bluecross
PolicyDiagnostic Testing of Common Sexually Transmitted Infections
Policy CodePolicy AHS - G2157
Change TypeNo material change
Effective Date
Next Review Date
Key ActionVerify benefit coverage and any prior authorization requirements at the time of request and document relevant clinical information to support testing.
HPV Testing: High-risk HPV testing (including genotyping assays) can be used according to cancer screening and diagnostic indications (age-based) and as adjunctive testing with cytology; HPV testing is not indicated as a general STI screen in asymptomatic persons or for diagnosing genital warts.
M. genitalium and Multiplex NAATs: FDA-cleared NAATs for Mycoplasma genitalium are appropriate for men with recurrent NGU and women with recurrent cervicitis; multiplex NAAT assays that detect CT, NG, MG, and TV meet coverage when used for individuals who meet covered clinical indications.
PrEP-related Testing Reminder: Confirm HIV negative status with antigen/antibody testing within one week before initiating or re-initiating PrEP; document baseline renal function and HBV screening per CDC guidance.
Gonorrhea: NAAT is the recommended test for urogenital infection; culture remains necessary for suspected treatment failure and for antimicrobial susceptibility; perform NAAT test-of-cure only in selected circumstances (e.g., pharyngeal infection at ~14 days).
Mycoplasma genitalium: Use FDA-cleared NAAT for men with recurrent NGU and women with recurrent cervicitis; consider testing in PID; resistance testing recommended when available; culture is impractical.
HPV and HSV testing: HPV testing is indicated per age-based cervical cancer screening guidance (e.g., primary or cotesting in persons 30–65); HPV testing is not for routine asymptomatic STI screening in men or younger women. HSV DNA detection (NAAT) is preferred over culture for lesion diagnosis; serology is not recommended for routine screening of asymptomatic patients.
Syphilis serology follow-up schedule
Follow-up schedule for primary/secondary/early latent syphilisRepeat serologic testing at 1, 3, 6, and 12 months after treatment.
Follow-up schedule for late latent syphilisRepeat serologic testing at 12 and 24 months after treatment.
Test-of-cure considerationsUse quantitative non-treponemal tests (RPR/VDRL) to monitor treatment response per the follow-up schedule.
Syphilis reflex testing: follow recommended algorithms — when a treponemal test (TT) is used alone and is positive, perform a reflex quantitative non-treponemal test (NTT) on the same serum (quantitative RPR/VDRL to at least 1:8–1:16 dilution). If NTT is primary and positive, reflex to a treponemal test. If both TT and NTT are used, ensure NTT is quantitative when positive or discrepant. Repeat testing timing (e.g., repeat after 1 month if TT positive and NTT negative with no high suspicion).
Neurosyphilis/ocular syphilis evaluation: patients with neurologic, ocular, or otologic signs should undergo appropriate evaluation including CSF analysis and CSF-VDRL when indicated; ocular symptoms warrant full slit-lamp and ophthalmologic examination and consideration of CSF testing if cranial nerve dysfunction is present. Document symptoms prompting specialist referral and results.
For gonorrhea treatment failures or nonresponse to initial therapy, culture testing for Neisseria gonorrhoeae with antimicrobial susceptibility testing MEETS COVERAGE CRITERIA and should be performed to guide management. Document prior treatment, timing, and clinical course.
Follow CDC stepwise PrEP monitoring schedule: HIV testing and adherence/risk-reduction counseling every 3 months, serum creatinine at baseline and at 3 months then up to every 6 months, site-based NAAT screening for gonorrhea/chlamydia per exposure site on recommended cadence, syphilis serology and pregnancy testing per CDC intervals. Document all test dates and results in the record.
Rapid NAAT (near-patient/point-of-care NAAT such as GeneXpert) is preferred in acute/emergency settings when timely results will change same-day management; document clinical rationale for rapid testing and specimen site.
If this policy conflicts with an applicable government coverage determination (e.g., LCD, NCD, state Medicaid), follow the government policy for that member; document the applicable government policy reference when different from this policy.
Type-specific gG2 assays are useful for diagnosing HSV-2 in persons with recurrent/atypical lesions, negative lesion PCR/culture, or when partner has genital herpes; routine serologic screening of asymptomatic persons is not recommended.
LimitationsHigh false-positive rates can occur in low-prevalence populations; interpret results with clinical context as per CDC guidance.
NAAT (molecular technique) definition
NAAT as molecular techniqueNAAT denotes nucleic acid amplification methods (e.g., PCR, TMA, SDA) that amplify and detect pathogen-specific nucleic acid sequences for diagnostic use.
Specimen typesCan be performed on urine, urethral/vaginal/cervical swabs and, when validated, on pharyngeal and rectal specimens.
Role in diagnosisPreferred method for detection of chlamydia and gonorrhea due to superior sensitivity and specificity compared with antigen-based POCTs.
Two-tier syphilis testing definition
Two-tier syphilis testing (definition)Use of both a treponemal test (TT) and a non-treponemal test (NTT) for diagnosis/screening—examples include EIA/TPPA/CLIA (treponemal) plus RPR/VDRL (nontreponemal).
PurposeCombining TT and NTT increases diagnostic accuracy across disease stages; use both for presumptive diagnosis and follow-up.
Algorithm notesIf TT alone is used and positive, perform reflex quantitative NTT on same serum; if NTT alone is used and positive, reflex TT should be performed.
Presumptive syphilis diagnosis definition
Presumptive syphilis diagnosisA presumptive diagnosis requires two laboratory serologic tests: a nontreponemal test (VDRL or RPR) and a treponemal test (TP-PA, EIA/CLIA, immunoblot, or rapid treponemal assay).
When direct detection appliesDirect detection (darkfield, PCR) is the gold standard for lesion-based early or congenital syphilis but serology is used for presumptive diagnosis when lesions are absent.
Risk of single-test useUse of only one serologic test (NTT or TT) is insufficient and can lead to false-negative or false-positive results.
HSV serologic screening definition and limitations
HSV serologic screening definitionType-specific HSV serologic assays detect prior exposure (antibodies) to HSV-1 or HSV-2 and are type-specific (e.g., gG2 for HSV-2).
Clinical limitationsSerologic screening in asymptomatic individuals is not recommended due to high false-positive rates and potential psychosocial harms; tests are useful in specific clinical scenarios only.
Role relative to lesion testingFor active lesions, NAAT/PCR or culture of lesion swabs is preferred for diagnosis and typing rather than relying on serology alone.
Direct detection methods for T. pallidum
Direct detection methods for T. pallidumDefinitive diagnostic methods include darkfield microscopy, PCR/NAAT of lesion material, and immunohistochemistry on tissue specimens; these provide direct identification of treponemes.
Availability and caveatsCommercial direct-detection molecular NAATs for T. pallidum are not widely available; locally developed validated PCR assays exist but require strict validation and quality controls.
Routine roleDirect detection is preferred for early or congenital syphilis when lesion material is available; serology remains standard for presumptive diagnosis when lesions are absent.
Treponemal vs non-treponemal tests
Treponemal (TT) vs non-treponemal (NTT) testsTreponemal tests detect antibodies specific to T. pallidum (e.g., TPPA, EIA/CLIA); non-treponemal tests (RPR, VDRL) detect non-specific antibodies and are quantitative for monitoring disease activity/treatment.
Clinical useTTs are more sensitive in early infection and detect prior treated infection; NTTs are used quantitatively for treatment monitoring and test-of-cure.
Reflex testing guidanceWhen TT is positive, perform reflex quantitative NTT; when NTT is used as screening and positive, follow with reflex TT.
NAAT recommended as primary diagnostic method
NAAT recommended as primary diagnostic method (scope)NAAT is the primary recommended diagnostic method for chlamydia and gonorrhea, performed on urine and genital swabs and, when validated, on extragenital specimens.
RationaleNAATs offer superior sensitivity and specificity compared with antigen-based POCTs and are endorsed by guideline bodies (CPS, BASHH, IUSTI, CDC).
ExceptionsCulture remains necessary for antimicrobial susceptibility testing in suspected gonorrhea treatment failures and for medico-legal confirmation.
Two-test syphilis algorithm definition
Two-test syphilis algorithm (definition)A treponemal-specific screening assay (EIA/CLIA) followed by confirmation with a different treponemal test and a quantitative non-treponemal test (RPR/VDRL) when indicated.
PurposeThis approach supports screening in asymptomatic populations while enabling quantitative NTTs for activity assessment and follow-up.
When to repeatIf TT positive and NTT negative without suspicion of early infection, repeat both tests at 1 month; reflex quantitative NTT should be performed if not initially done.
Multiplex amplified probe technique definition
Multiplex amplified probe techniqueA multiplex amplified probe technique is a NAAT method that simultaneously amplifies and detects multiple STI targets and reports each pathogen as detected or not detected for specified specimen types (urine, vaginal, pharyngeal, rectal).
Commercial examplesProprietary assays include Cepheid Xpert® CT/NG and Abbott Alinity m STI Assay, which are listed with specific CPT/HCPCS codes.
Typical specimen typesUsed on urine, endocervical/vaginal swabs and, when validated, pharyngeal and rectal swabs.
RPR immunoassay definition
RPR immunoassay (definition)A non-treponemal antibody (RPR) immunoassay detects non-treponemal antibodies and can be performed as a quantitative assay for monitoring syphilis treatment response.
Proprietary assays citedBioPlex 2200 Syphilis Total & RPR Assay (0064U/0065U/0210U) is listed as a proprietary immunoassay in the policy.
Clinical roleQuantitative RPR values are used for test-of-cure and to assess decline in antibody titers post-treatment.
Guideline and regulatory sources
Primary guideline sources referencedCDC, USPSTF, IUSTI, BASHH, Canadian Paediatric Society (CPS), and FDA materials are cited as guideline and regulatory sources informing the policy.
UsageThese sources provide recommendations on screening intervals, diagnostic algorithms (two-tier syphilis testing), and specimen/testing modality preferences (NAAT preferred for CT/NG).
Reference list locationFull bibliographic citations appear in the policy references section (e.g., FDA 510(k) summaries and guideline publications).